Florida Cancer Specialists & Research Institute, Core Ventures Turn Vision into Value
Fort Myers, Fla., April 5, 2024 –Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to share that its financial performance for the first two months of 2024 has surpassed the statewide practice’s budget. FCS, Florida’s largest community oncology practice, attributes much of its success to the formation of Community Oncology Revitalization Enterprise, LLC (Core Ventures), FCS’ management services organization (MSO) that was established at the start of the year. These results underscore the efficacy of Core Venture’s framework in navigating market challenges and driving sustainable growth for FCS.
Despite recent setbacks incurred due to the Change Healthcare crisis, where FCS strategically leveraged Core Ventures partnerships to develop a quick-turn resolution, FCS has been able to achieve outstanding results across key financial metrics.
“Through streamlined operations, enhanced resource allocation, and optimized decision-making processes, FCS has demonstrated resilience and adaptability in capitalizing on market opportunities,” said FCS Chief Executive Officer Nathan H. Walcker.
Recognizing the evolving oncology landscape, FCS has strategically allocated resources toward initiatives that align with its long-term growth objectives.
Over the past three months, the practice has expanded its breadth of expertise by welcoming new physicians, including FCS Medical Director, Late Phase Clinical Research Bradley Monk, MD, who is focused on building out FCS’ disease-specific late-phase research programs.
Additionally, in an announcement made earlier this week, FCS introduced a new healthcare analytics subsidiary of Core Ventures, Vita Nova Insights,SM which utilizes precision oncology insights and real-world evidence to optimize patient care and propel clinical research to aid in the discovery and development of new therapies.
Further initiatives brought to fruition early in the year are the dedicated efforts to enhance value-based care programs within the practice have also been impactful, including the launch of the FCS Holistic Model of Care. The patient-centric program aimed at improving the quality of oncology care and reducing healthcare costs provides all FCS patients, regardless of their health plan, with care coordination and supportive services to optimize their outcomes.
“The establishment of Core Ventures has enabled FCS to harness opportunities that will sustain and enrich the value we are providing to our shareholders, our strategic partners, and our patients,” says FCS President & Managing Physician Lucio N. Gordan, MD. “I could not be more proud of the initial results of these critical programs, which will continue to pave the way for enhanced patient care and practice efficiency.”
FCS and Core Ventures remain steadfast in their commitment to excellence, which will create long-term value for its shareholders, partners, and patients. Together, they are well-positioned for sustained growth and competitive advantage.
Physicians who may be interested in how they may benefit from participation in Florida Cancer Specialists & Research Institute and Core Ventures may reach out directly by emailing CoreVentures@FLCancer.com.
Petosemtamab and Pembrolizumab: A Promising Pair in HNSCC Treatment
July 2nd 2024In an interview, Cesar Augusto Perez, MD, delved into the findings from a phase 2 study evaluating petosemtamab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Read More